ReviewCurrent opinion in infectious diseases2018
Recent insights into Shigella.
Review in Current opinion in infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- Burden of Shigella among children with diarrhea in the Americas: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Hygiene practices among young adolescents aged 12-15 years in low- and middle-income countries: a population-based study.Journal of global health · 2020Pooled it
- Gamma Irradiation Effects on Fatty Acid Profiles, Adhesion, Plasmid Stability, and Secreted Proteins inMicroorganisms · 2026Article
- Multifunctional antibody responses from a primateScience translational medicine · 2026Article
- Global distribution and genomic characteristics ofInfectious medicine · 2026Article
- Shigella and Guillain-Barré syndrome: Reconsidering an overlooked link.The Indian journal of medical research · 2026Review
- Protocols for genomic epidemiology and source attribution of enteric bacteria causing diarrhoeal disease across Africa.BMJ open · 2026Article
- Article
- Anti-Shigella activity and killing kinetics of compounds from MMV Pathogen and COVID Boxes: Identifying leads against Shigellosis.Current research in pharmacology and drug discovery · 2026Article
- Temporal trends ofFrontiers in public health · 2026Observational
- Trimethoprim-Sulfamethoxazole and Azithromycin Resistance inInfection and drug resistance · 2026Article
- Genomic and epidemiological characteristics ofPathogens and global health · 2025Article
- Shigella type-III secretion system effectors counteract the induction of host inflammation and cell death.The EMBO journal · 2025Article
- Article
- Bacteremic vs NonbacteremicOpen forum infectious diseases · 2025Article
- Epidemiological Characteristics and Influencing Factors of Bacillary Dysentery Outbreaks - China, 2008-2024.China CDC weekly · 2025Article
- Cinnamaldehyde supplementation in sows and their offspring: effects on colostrum and milk composition, performance, redox status and intestinal health.Journal of animal science and biotechnology · 2025Article
- Prevalence of intestinal parasites,IJID regions · 2025Article
- Effects of a healthy diet based on seed-rich vegetables on the gut microbiota and intrinsic brain activity in perimenopausal women: A pilot study on cognitive improvement.Scientific reports · 2025Article
- Characteristics and potential diagnostic value of gut microbiota in ovarian tumor patients.Scientific reports · 2025Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 4 countries.
Funding
Abstract
purpose of reviewDiarrhoea is a major global health problem, and recent studies have confirmed Shigella as a major contributor to this burden. Here, we review recent advances in Shigella research; focusing on their epidemiology, pathogenesis, antimicrobial resistance, and the role of the gut microbiome during infection. RECENT
findingsEnhanced epidemiological data, combined with new generation diagnostics, has highlighted a greater burden of Shigella disease than was previously estimated, which is not restricted to vulnerable populations in low-middle income countries. As we gain an ever more detailed insight into the orchestrated mechanisms that Shigella exploit to trigger infection, we can also begin to appreciate the complex role of the gut microbiome in preventing and inducing such infections. The use of genomics, in combination with epidemiological data and laboratory investigations, has unravelled the evolution and spread of various species. Such measures have identified resistance to antimicrobials as a key contributor to the success of specific clones. SUMMARY: We need to apply novel findings towards sustainable approaches for treating and preventing Shigella infections. Vaccines and alternative treatments are under development and may offer an opportunity to reduce the burden of Shigella disease and restrict the mobility of antimicrobial resistant clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.